FIELD: immunology.
SUBSTANCE: invention relates to immunology. Disclosed is a monoclonal antibody that binds the KIR3DL2 polypeptide, as well as a pharmaceutical composition containing same and method for the treatment or prevention of diseases accompanied by the expression of KIR3DL2.
EFFECT: said antibodies have higher stability and are suitable for the treatment of disorders characterised by cells expressing KIR3DL2, in particular, CD4+ T cells, including malignant tumours, for example, fungoid granuloma and Sezary syndrome, as well as autoimmune disorders, accompanied by the expression of KIR3DL2.
15 cl, 2 dwg, 10 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| KIR3DL2 BINDING AGENTS | 2013 |
|
RU2682449C2 |
| HUMANISED ANTI-LIGHT ANTIBODIES AND USING THEM | 2010 |
|
RU2542394C2 |
| METHODS OF TREATING CONDITIONS WITH ANTIBODIES THAT BIND COLONY STIMULATING FACTOR 1 RECEPTOR (CSF1R) | 2012 |
|
RU2670743C9 |
| HUMANISED ANTIBODIES TO AMYLOID BETA | 2008 |
|
RU2567151C2 |
| ANTI-KIT ANTIBODIES AND USES THEREOF | 2013 |
|
RU2681730C2 |
| BINDING PROTEINS AND METHODS FOR USE THEREOF | 2015 |
|
RU2701434C2 |
| APPLICATION OF ANTIBODY AGAINST AMYLOID-BETA IN CASE OF EYE DISEASES | 2008 |
|
RU2571859C2 |
| PROTEINS BINDING SPECIFIC MEMBRANE PROSTATE ANTIGEN, AND RELATED COMPOSITIONS AND METHODS | 2012 |
|
RU2632647C2 |
| MICA BINDING AGENTS | 2013 |
|
RU2656183C2 |
| HUMANIZING RABBIT ANTIBODIES USING A UNIVERSAL ANTIBODY FRAMEWORK | 2018 |
|
RU2696202C1 |
